MX2021013669A - Ligandos peptidicos biciclicos especificos para ox40. - Google Patents

Ligandos peptidicos biciclicos especificos para ox40.

Info

Publication number
MX2021013669A
MX2021013669A MX2021013669A MX2021013669A MX2021013669A MX 2021013669 A MX2021013669 A MX 2021013669A MX 2021013669 A MX2021013669 A MX 2021013669A MX 2021013669 A MX2021013669 A MX 2021013669A MX 2021013669 A MX2021013669 A MX 2021013669A
Authority
MX
Mexico
Prior art keywords
peptide ligands
drug conjugates
complexes
peptide
subtended
Prior art date
Application number
MX2021013669A
Other languages
English (en)
Spanish (es)
Inventor
Peter Park
Liuhong Chen
Kevin Mcdonnell
Nicholas KEEN
Tom Li Stephen
Helen Harrison
Michael Skynner
Harvey Che
Original Assignee
Bicycletx Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bicycletx Ltd filed Critical Bicycletx Ltd
Publication of MX2021013669A publication Critical patent/MX2021013669A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
MX2021013669A 2019-05-09 2020-05-11 Ligandos peptidicos biciclicos especificos para ox40. MX2021013669A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962845473P 2019-05-09 2019-05-09
PCT/GB2020/051144 WO2020225577A1 (en) 2019-05-09 2020-05-11 Bicyclic peptide ligands specific for ox40

Publications (1)

Publication Number Publication Date
MX2021013669A true MX2021013669A (es) 2021-12-10

Family

ID=70847426

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021013669A MX2021013669A (es) 2019-05-09 2020-05-11 Ligandos peptidicos biciclicos especificos para ox40.

Country Status (12)

Country Link
US (1) US11613560B2 (cg-RX-API-DMAC7.html)
EP (1) EP3965827A1 (cg-RX-API-DMAC7.html)
JP (1) JP2022532134A (cg-RX-API-DMAC7.html)
KR (1) KR20220007098A (cg-RX-API-DMAC7.html)
CN (1) CN113811541A (cg-RX-API-DMAC7.html)
AU (1) AU2020269506A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021022315A2 (cg-RX-API-DMAC7.html)
CA (1) CA3137095A1 (cg-RX-API-DMAC7.html)
IL (1) IL287881A (cg-RX-API-DMAC7.html)
MX (1) MX2021013669A (cg-RX-API-DMAC7.html)
SG (1) SG11202111606TA (cg-RX-API-DMAC7.html)
WO (1) WO2020225577A1 (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ731185A (en) 2014-10-29 2024-03-22 Bicyclerd Ltd Bicyclic peptide ligands specific for mt1-mmp
WO2019002842A1 (en) 2017-06-26 2019-01-03 Bicyclerd Limited BICYCLIC PEPTIDE LIGANDS WITH DETECTABLE FRACTIONS AND USES THEREOF
JP7670481B2 (ja) 2017-08-04 2025-04-30 バイスクルテクス・リミテッド Cd137に対して特異的な二環式ペプチドリガンド
TWI825046B (zh) 2017-12-19 2023-12-11 英商拜西可泰克斯有限公司 Epha2特用之雙環胜肽配位基
CA3091775A1 (en) 2018-02-23 2019-08-29 Bicycletx Limited Multimeric bicyclic peptide ligands
GB201810316D0 (en) 2018-06-22 2018-08-08 Bicyclerd Ltd Peptide ligands for binding to EphA2
US11180531B2 (en) 2018-06-22 2021-11-23 Bicycletx Limited Bicyclic peptide ligands specific for Nectin-4
GB201820325D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for psma
GB201820288D0 (en) 2018-12-13 2019-01-30 Bicycle Tx Ltd Bicycle peptide ligaands specific for MT1-MMP
GB201820295D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for MT1-MMP
WO2020128527A1 (en) 2018-12-21 2020-06-25 Bicyclerd Limited Bicyclic peptide ligands specific for pd-l1
EP3897849A1 (en) 2018-12-21 2021-10-27 BicycleTx Limited Bicyclic peptide ligands specific for pd-l1
GB201900529D0 (en) 2019-01-15 2019-03-06 Bicycletx Ltd Bicyclic peptide ligands specific for CD38
KR20220007098A (ko) 2019-05-09 2022-01-18 바이사이클티엑스 리미티드 Ox40에 특이적인 이환식 펩티드 리간드
TWI860386B (zh) 2019-07-30 2024-11-01 英商拜西可泰克斯有限公司 異質雙環肽複合物
SI4464721T1 (sl) * 2019-10-03 2025-08-29 Bicycletx Limited Heterotandemski biciklični peptidni kompleksi
CN116348476A (zh) 2020-08-03 2023-06-27 拜斯科技术开发有限公司 基于肽的接头
CA3206529A1 (en) * 2021-01-08 2022-07-14 Bicycletx Limited Heterotandem bicyclic peptide complexes
JP2024504068A (ja) * 2021-01-08 2024-01-30 バイスクルテクス・リミテッド 抗感染性二環式ペプチドリガンド
US12539335B2 (en) 2021-09-29 2026-02-03 Conjustar (Zhuhai) Biologics Co., Ltd. Tricyclic polypeptide conjugated drug and use thereof
CN114933638B (zh) * 2022-05-12 2024-07-26 厦门大学 特异性靶向cd28的多元环肽配体框架

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6927203B1 (en) 1999-08-17 2005-08-09 Purdue Research Foundation Treatment of metastatic disease
EP1452868A2 (en) 2003-02-27 2004-09-01 Pepscan Systems B.V. Method for selecting a candidate drug compound
JP6074574B2 (ja) 2008-02-05 2017-02-08 バイシクル セラピューティクス リミテッド 方法及び組成物
GB0913775D0 (en) 2009-08-06 2009-09-16 Medical Res Council Multispecific peptides
WO2012057624A1 (en) 2010-10-25 2012-05-03 Pepscan Systems B.V. Novel bicyclic peptide mimetics
US9828432B2 (en) * 2012-02-06 2017-11-28 Providence Health & Services—Oregon Cancer treatment and monitoring methods using OX40 agonists
ES2705068T3 (es) 2013-05-23 2019-03-21 Ohio State Innovation Foundation Síntesis química y cribado de bibliotecas de péptidos bicíclicos
PT3149025T (pt) 2014-05-21 2019-08-01 Entrada Therapeutics Inc Peptídeos penetrantes de células e métodos de fabrico e utilização dos mesmos
NZ731185A (en) 2014-10-29 2024-03-22 Bicyclerd Ltd Bicyclic peptide ligands specific for mt1-mmp
MX2017016844A (es) * 2015-07-16 2018-08-15 Biokine Therapeutics Ltd Composiciones y procedimientos para tratar cancer.
KR102775461B1 (ko) 2016-04-01 2025-02-28 어비디티 바이오사이언시스 인크. 핵산-폴리펩타이드 조성물 및 이의 용도
BR112018071612A2 (pt) 2016-04-22 2019-02-19 Alligator Bioscience Ab polipeptídeos biespecíficos inovadores contra cd137
GB201607827D0 (en) * 2016-05-04 2016-06-15 Bicycle Therapeutics Ltd Bicyclic peptide-toxin conjugates specific for MT1-MMP
EP3559018A1 (en) 2016-12-23 2019-10-30 Bicyclerd Limited Peptide derivatives having novel linkage structures
BR112019017628A2 (pt) 2017-02-24 2020-07-07 Macrogenics, Inc. molécula de ligação a cd137 x ta, composições farmacêuticas, uso da molécula de ligação a cd137 x ta, molécula de ligação a cd137, uso da molécula de ligação a cd137, molécula de ligação a her2/neu, uso da molécula de ligação a her2/neu, e uso de uma composição
JP7670481B2 (ja) 2017-08-04 2025-04-30 バイスクルテクス・リミテッド Cd137に対して特異的な二環式ペプチドリガンド
TWI825046B (zh) 2017-12-19 2023-12-11 英商拜西可泰克斯有限公司 Epha2特用之雙環胜肽配位基
GB201721265D0 (en) 2017-12-19 2018-01-31 Bicyclerd Ltd Bicyclic peptide ligands specific for EphA2
CA3091775A1 (en) 2018-02-23 2019-08-29 Bicycletx Limited Multimeric bicyclic peptide ligands
CA3095582A1 (en) 2018-04-04 2019-10-10 Bicycletx Limited Heterotandem bicyclic peptide complexes
US11180531B2 (en) 2018-06-22 2021-11-23 Bicycletx Limited Bicyclic peptide ligands specific for Nectin-4
GB201810316D0 (en) 2018-06-22 2018-08-08 Bicyclerd Ltd Peptide ligands for binding to EphA2
WO2020084305A1 (en) 2018-10-23 2020-04-30 Bicycletx Limited Bicyclic peptide ligands and uses thereof
EP3897849A1 (en) 2018-12-21 2021-10-27 BicycleTx Limited Bicyclic peptide ligands specific for pd-l1
US20220184222A1 (en) 2019-04-02 2022-06-16 Bicycletx Limited Bicycle toxin conjugates and uses thereof
KR20220007098A (ko) 2019-05-09 2022-01-18 바이사이클티엑스 리미티드 Ox40에 특이적인 이환식 펩티드 리간드
TWI860386B (zh) 2019-07-30 2024-11-01 英商拜西可泰克斯有限公司 異質雙環肽複合物
SI4464721T1 (sl) 2019-10-03 2025-08-29 Bicycletx Limited Heterotandemski biciklični peptidni kompleksi
CN114760988A (zh) 2019-11-27 2022-07-15 拜斯科技术开发有限公司 对EphA2具有特异性的双环肽配体和其用途
EP4165414A1 (en) 2020-06-12 2023-04-19 BicycleTX Limited Treatment of diseases characterized by overexpression of erythropoietin-producing hepatocellular receptor a2 (epha2)

Also Published As

Publication number Publication date
US20200354406A1 (en) 2020-11-12
CN113811541A (zh) 2021-12-17
WO2020225577A1 (en) 2020-11-12
BR112021022315A2 (pt) 2021-12-28
AU2020269506A1 (en) 2022-01-06
EP3965827A1 (en) 2022-03-16
KR20220007098A (ko) 2022-01-18
SG11202111606TA (en) 2021-11-29
JP2022532134A (ja) 2022-07-13
CA3137095A1 (en) 2020-11-12
US11613560B2 (en) 2023-03-28
IL287881A (en) 2022-01-01

Similar Documents

Publication Publication Date Title
PH12020552179A1 (en) Bicyclic peptide ligands specific for nectin-4
SA520420008B1 (ar) جزيئات ترابطية ببتيدية ثنائية الحلقات متعددة الوحدات
PH12020550929A1 (en) Bicyclic peptide ligands specific for epha2
BR112021022315A2 (pt) Ligantes de peptídeo bicíclicos específicos para ox40
MX2021006989A (es) Ligandos peptidicos biciclicos especificos para metaloproteasa tipo 1 de membrana (mt1-mmp).
WO2022148974A3 (en) Bicyclic peptide ligands specific for nk cells
MX2021006991A (es) Ligandos peptidicos biciclicos especificos para metaloproteasa tipo 1 de membrana (mt1-mmp).
MX2022004572A (es) Conjugados farmacologicos de ligandos peptidicos biciclicos.
NZ731185A (en) Bicyclic peptide ligands specific for mt1-mmp
SA522431587B1 (ar) مــركب ببتيد ثنائي الحلقة متغاير الترادف
MX2023005624A (es) Ligandos peptidicos biciclicos especificos para el receptor de transferrina 1 (tfr1).
MX2020010444A (es) Complejos de péptidos bicíclicos en heterotándem.
EP3882270A3 (en) Proteins binding nkg2d, cd16, and egfr, ccr4, or pd-l1
PH12014500902A1 (en) Hla-a* 1101-restricted wt1 peptide and pharmaceutical composition comprising the same
MX2023008168A (es) Complejos peptidicos biciclicos heterotandem.
JP2016527286A5 (cg-RX-API-DMAC7.html)
MX2021009189A (es) Belantamab mafodotin en combinación con pembrolizumab para el tratamiento del cáncer.
EA202190105A1 (ru) Бициклические пептидные лиганды, специфичные к нектину-4
EA202091991A1 (ru) Мультимерные бициклические пептидные лиганды
EA202091375A1 (ru) БИЦИКЛИЧЕСКИЕ ПЕПТИДНЫЕ ЛИГАНДЫ, ОБЛАДАЮЩИЕ СПЕЦИФИЧНОСТЬЮ К EphA2
EA202191660A1 (ru) Бициклические пептидные лиганды, специфичные к mt1-mmp
TH2001007117A (th) ลิแกนด์ เปปไทด์ ไบไซคลิกที่จำเพาะสำหรับเนคทิน-4
AR113966A1 (es) LIGANDOS PÉPTIDOS BICÍCLICOS ESPECÍFICOS PARA EphA2
AR115601A1 (es) Ligandos peptídicos bicíclicos específicos para nectina-4